We highlight subsite-specific effects, such as rectal cancer risk linked to LAMC1, a clinically actionable drug target, and identify CCM2 expression as a female-specific CRC risk factor involved in progesterone signalling. This evidence concerns the gene CCM2 and colorectal carcinoma.